Expert Interview
Digging into the recent data from ASH2022 on Syndax' revumenib (SNDX-5613) & Kura's ziftomenib in treating AML
Ticker(s): SNDX, KURAInstitution: Washington University St. Louis
- Professor Department of Medicine Oncology Division Bone Marrow Transplantation & Leukemia at WUSTL
- Currently treats ~300 patients with multiple myeloma, 25 patients with AML, 10 patients with CMML, and ~15 patients per month with AL Amyloidosis.
- Clinical research focus on strategies to improve the outcome of patients with multiple myeloma, acute myeloid leukemia, and myelodysplastic syndromes.
How does the data released for revemunib compare to that released for ziftomenib?
Added By: max_adminWhat are the current options for treating AML? How do they compare to these new potential drugs?
Added By: max_adminOn a scale of 1 to 10 how excited are you for these drugs going forward?
Added By: max_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
